Actemra Looks Promising in Scleroderma
Encouraging results were seen for tocilizumab (Actemra) in the treatment of diffuse systemic sclerosis (SSc) in a proof-of-concept study by Christopher P. Denton, MBBS, of University College Londo.
At 24 weeks, a numerically favorable response was seen on modified Rodnan skin scores and lung fibrosis among patients randomized to tocilizumab compared with those receiving placebo. The study is now continuing with a phase III trial that includes a greater number of patients.
news & events
Skin care is very important when you have systemic sclerosis.
Come with us on a roadtrip along with Scleroderma Framed in order to spread awareness of Scleroderma.
Find reliable information on scleroderma & COVID-19, official pages with information and much more.